News

By Scott Meacham There is very big news this month for individuals and families affected by sickle cell disease (SCD). The U.S. Food and Drug Administration (FDA) has approved the first targeted treatment to reduce the frequency of pain crises in individuals living with SCD. This new drug — Adakveo® from Novartis — decreases theRead more

Robert Broyles, in his work at the OU Health Science Center and National Institutes of Health, discovered that a molecule called ferritin-H would likely cause the switch back to fetal hemoglobin.

Oklahoma City’s EpimedX is tackling a devastating genetic disease that affects millions of people around the world.